Production (Stage)
Moleculin Biotech, Inc.
MBRX
$0.67
-$0.0201-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.23% | -12.28% | -16.23% | -15.47% | -16.89% |
| Depreciation & Amortization | -4.62% | -2.34% | 3.20% | 4.00% | 1.56% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.33% | -10.09% | 4.16% | -10.26% | -12.42% |
| Operating Income | 7.33% | 10.09% | -4.16% | 10.26% | 12.42% |
| Income Before Tax | 13.40% | 26.89% | -14.77% | 14.02% | 10.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.40% | 26.89% | -14.77% | 14.02% | 10.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.40% | 26.89% | -14.77% | 14.02% | 10.80% |
| EBIT | 7.33% | 10.09% | -4.16% | 10.26% | 12.42% |
| EBITDA | 7.35% | 10.13% | -4.16% | 10.31% | 12.48% |
| EPS Basic | 56.64% | 53.92% | 13.80% | 23.57% | 17.79% |
| Normalized Basic EPS | 56.64% | 53.92% | 13.80% | 23.57% | 17.79% |
| EPS Diluted | 56.64% | 53.92% | 13.80% | 23.57% | 17.79% |
| Normalized Diluted EPS | 56.64% | 53.92% | 13.80% | 23.57% | 17.79% |
| Average Basic Shares Outstanding | 144.23% | 74.18% | 37.87% | 16.88% | 10.63% |
| Average Diluted Shares Outstanding | 144.23% | 74.18% | 37.87% | 16.88% | 10.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |